Journal of Clinical Oncology, Vol 24, No 18 (June 20), 2006: pp. 2750-2756
© 2006 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.02.3028
Use and Outcomes of Adjuvant Chemotherapy in Older Women With Breast Cancer
Sharon H. Giordano,
Zhigang Duan,
Yong-Fang Kuo,
Gabriel N. Hortobagyi,
James S. Goodwin
From the Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston; and the Department of Internal Medicine, The University of Texas Medical Branch at Galveston, Galveston, TX
Address reprint requests to Sharon H. Giordano, MD, MPH, M.D. Anderson Cancer Center, PO Box 301439, Unit 1354, Houston, TX 77230; e-mail: sgiordan{at}mdanderson.org
PURPOSE: This study was undertaken to determine patterns and outcomes of adjuvant chemotherapy use in a population-based cohort of older women with primary breast cancer.
PATIENTS AND METHODS: Women were identified from the Surveillance, Epidemiology, and End ResultsMedicare-linked database who met the following criteria: age 65 years, stage I to III breast cancer, and diagnosis between 1991 and 1999. Adjuvant chemotherapy use was ascertained by Common Procedural Terminology J codes. Logistic regression analysis was performed to determine factors associated with chemotherapy use. Multivariate Cox proportional hazards models were used to calculate the hazard of death for women with and without chemotherapy.
RESULTS: A total of 41,390 women met study criteria, of whom 4,500 (10.9%) received chemotherapy. The use of adjuvant chemotherapy more than doubled during the 1990s, from 7.4% in 1991 to 16.3% in 1999 (P < .0001), with a significant shift toward anthracycline use. Women who were younger, white, with lower comorbidity scores, more advanced stage disease, and estrogen receptor (ER) negative disease were significantly more likely to receive chemotherapy. Chemotherapy was not associated with improved survival among women with lymph nodenegative (LN) disease or LN-positive, ER-positive disease (hazard ratio [HR], 1.05; 95% CI, 0.85 to 1.31). However, among women with LN-positive, ER-negative breast cancer, chemotherapy was associated with a significant reduction in breast cancer mortality (HR, 0.72; 95% CI, 0.54 to 0.96). A similar significant benefit of chemotherapy was seen in the subset of women age 70 years or older (HR, 0.74; 95% CI, 0.56 to 0.97).
CONCLUSION: In this observational cohort, chemotherapy was associated with a significant reduction in mortality among older women with ER-negative, LN-positive breast cancer.
Supported in part by National Institutes of Health Grant No. 1K07 CA 109064-01 (to S.H.G) and the Center on Population Health and Health Disparities Grant No. P50CA105631.
Authors disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
G. Beadle, P. Baade, and L. Fritschi
Acute myeloid leukemia after breast cancer: a population-based comparison with hematological malignancies and other cancers
Ann. Onc.,
January 1, 2009;
20(1):
103 - 109.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Warren, A. B. Mariotto, A. Meekins, M. Topor, and M. L. Brown
Current and Future Utilization of Services From Medical Oncologists
J. Clin. Oncol.,
July 1, 2008;
26(19):
3242 - 3247.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. A. Ganz, M. A. Hussey, C. M. Moinpour, J. M. Unger, L. F. Hutchins, S. R. Dakhil, J. K. Giguere, J. W. Goodwin, S. Martino, and K. S. Albain
Late Cardiac Effects of Adjuvant Chemotherapy in Breast Cancer Survivors Treated on Southwest Oncology Group Protocol S8897
J. Clin. Oncol.,
March 10, 2008;
26(8):
1223 - 1230.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. C. Pinder, Z. Duan, J. S. Goodwin, G. N. Hortobagyi, and S. H. Giordano
Congestive Heart Failure in Older Women Treated With Adjuvant Anthracycline Chemotherapy for Breast Cancer
J. Clin. Oncol.,
September 1, 2007;
25(25):
3808 - 3815.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Patt, Z. Duan, S. Fang, G. N. Hortobagyi, and S. H. Giordano
Acute Myeloid Leukemia After Adjuvant Breast Cancer Therapy in Older Women: Understanding Risk
J. Clin. Oncol.,
September 1, 2007;
25(25):
3871 - 3876.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Dellapasqua, M. Colleoni, M. Castiglione, and A. Goldhirsch
New Criteria for Selecting Elderly Patients for Breast Cancer Adjuvant Treatment Studies
Oncologist,
August 1, 2007;
12(8):
952 - 959.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Goldhirsch, W. C. Wood, R. D. Gelber, A. S. Coates, B. Thurlimann, H. -J. Senn, and Panel Members
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
Ann. Onc.,
July 1, 2007;
18(7):
1133 - 1144.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Bouchardy, E. Rapiti, S. Blagojevic, A.-T. Vlastos, and G. Vlastos
Older Female Cancer Patients: Importance, Causes, and Consequences of Undertreatment
J. Clin. Oncol.,
May 10, 2007;
25(14):
1858 - 1869.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. B. Muss, L. Biganzoli, D. J. Sargent, and M. Aapro
Adjuvant Therapy in the Elderly: Making the Right Decision
J. Clin. Oncol.,
May 10, 2007;
25(14):
1870 - 1875.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Crivellari, M. Aapro, R. Leonard, G. von Minckwitz, E. Brain, A. Goldhirsch, A. Veronesi, and H. Muss
Breast Cancer in the Elderly
J. Clin. Oncol.,
May 10, 2007;
25(14):
1882 - 1890.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. D. Crew, A. I. Neugut, X. Wang, J. S. Jacobson, V. R. Grann, G. Raptis, and D. L. Hershman
Racial Disparities in Treatment and Survival of Male Breast Cancer
J. Clin. Oncol.,
March 20, 2007;
25(9):
1089 - 1098.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. Silliman and P. A. Ganz
Adjuvant Chemotherapy Use and Outcomes in Older Women With Breast Cancer: What Have We Learned?
J. Clin. Oncol.,
June 20, 2006;
24(18):
2697 - 2699.
[Full Text]
[PDF]
|
 |
|
|